Aspira Women’s Health (NASDAQ:AWH) Earns Hold Rating from Analysts at StockNews.com

Investment analysts at StockNews.com assumed coverage on shares of Aspira Women’s Health (NASDAQ:AWH) in a research report issued to clients and investors on Wednesday. The firm set a “hold” rating on the stock.

Separately, Alliance Global Partners reduced their target price on Aspira Women’s Health from $7.00 to $5.50 and set a “buy” rating for the company in a report on Wednesday, August 14th.

Aspira Women’s Health Stock Performance

Shares of NASDAQ:AWH opened at $0.74 on Wednesday. Aspira Women’s Health has a 52-week low of $0.73 and a 52-week high of $5.65. The firm has a market capitalization of $11.89 million, a P/E ratio of -0.51 and a beta of 1.44. The stock has a 50 day moving average price of $0.86 and a 200-day moving average price of $1.44.

Aspira Women’s Health (NASDAQ:AWH) last posted its quarterly earnings data on Monday, August 12th. The company reported ($0.28) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.04. The company had revenue of $2.42 million for the quarter, compared to the consensus estimate of $2.60 million. During the same period last year, the business earned ($0.28) EPS. On average, equities analysts forecast that Aspira Women’s Health will post -1.26 EPS for the current fiscal year.

Hedge Funds Weigh In On Aspira Women’s Health

An institutional investor recently raised its position in Aspira Women’s Health stock. B. Riley Wealth Advisors Inc. grew its holdings in Aspira Women’s Health Inc. (NASDAQ:AWH) by 88.6% during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 236,396 shares of the company’s stock after acquiring an additional 111,022 shares during the period. B. Riley Wealth Advisors Inc. owned about 1.90% of Aspira Women’s Health worth $352,000 as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 12.19% of the company’s stock.

Aspira Women’s Health Company Profile

Aspira Women's Health Inc, together with its subsidiaries, discovers, develops, and commercializes of noninvasive AI-powered diagnostic tests for gynecologic diseases in the United States. The company's products include Ova1Plus, a qualitative serum test to assess the likelihood of malignancy in women with an ovarian adnexal mass; Overa, a biomarker test intended to maintain Ova1's high sensitivity; and OvaWatch, a laboratory developed tests to assist in the initial clinical assessment of malignancy risk in all women thought to have an indeterminate or benign adnexal mass.